FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/06/2023
Voltar para busca
Dado oficial do USPTO
ALBAJUNA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ALBAJUNA
ST13
US500000079326559Classe
5, 41, 42, 44
Pedido
79326559
Registro
6982504
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
13/06/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 41, 42, 44
Data de depósito
22/09/2021
Data de registro
21/02/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/02/2023
Última transação
21/02/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
ES
Examinador
TULLY, MATTHEW
Unidade examinadora
L50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
ALBAJUNA THERAPEUTICS, S.L.
Representantes
Ashly I. Boesche Pattishall, McAuliffe, Newbury, Hilliard
Classificação técnica
Classes Nice
Classe 5Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationsrecombinant therapeutics for the treatment of HIV/AIDS; biological preparations for medical userecombinant therapeutics for the treatment of HIV/AIDS; antiviral preparationsrecombinant therapeutics being pharmaceutical preparations in the nature of antivirals; pharmaceutical products for the treatment of HIV/AIDS; chemicalanalysis and diagnostic reagents for medical research and for medical and veterinary use in diagnostics; diagnosis preparations for medical purposesmedical diagnostic reagents; diagnostic testing materials for medical usediagnostic kits comprised of medical diagnostic recombinant reagents and assays for detecting diseases
Classe 41
Educational servicesproviding training in the field of medical and pharmaceutical products; organization and conducting of seminarsconferencescongressessymposiums and training workshops in the field of medical and pharmaceutical products; online publication of books and journals in the field of medical and pharmaceutical products in electronic formbeing publishing services; practical training in the field of medicine and pharmaceutical products; publication of texts other than advertising texts in the field of medicine and pharmaceutical products
Classe 42
Pharmaceutical research and development; medical research in the field of recombinant therapeutics; clinical research services in the field of pharmaceuticalsrecombinant therapeutics; laboratory research services relating to pharmaceuticals; research and development services relating to new pharmaceutical products; laboratory materials analysis services being medical and scientific laboratory services; chemical analysis; scientific laboratory services; laboratory testing servicesmedical and scientific laboratory services; medical research laboratory services; research and development services relating to pharmaceutical substances; technical consultancy in the pharmaceutical sectorconsulting services in the field of pharmaceutical research and development; online and in-person information and advisory services relating to the aforesaid
Classe 44
Monitoring of patientsmonitoring of medical data for medical diagnosis and treatment; advice in the field of beauty care; psychological assistance for patients; providing medical and health information about medical disorders; providing medical and health information about infection control; medical services for psychological counseling; patient support services in the nature of medical services relating to the treatment of medical disorders; medical services; providing health information; information and advisory services relating to pharmaceutical productsmedical and pharmaceutical consultation; online and in-person information and advisory services relating to the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/05/2023
FIMP
FINAL DISPOSITION PROCESSED
24/05/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/05/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
21/02/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
21/02/2023
GPNX
NOTIFICATION PROCESSED BY IB
12/12/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/12/2022
PUBO
PUBLISHED FOR OPPOSITION
06/12/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/11/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
23/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16/11/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/11/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
02/11/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/11/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
02/11/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/11/2022
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
02/11/2022
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
20/09/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/09/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
06/09/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/09/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
06/09/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/09/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/08/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/08/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/08/2022
RFNT
REFUSAL PROCESSED BY IB
26/07/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/07/2022
RFRR
REFUSAL PROCESSED BY MPU
01/07/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
29/06/2022
CNRT
NON-FINAL ACTION WRITTEN
28/06/2022
DOCK
ASSIGNED TO EXAMINER
24/06/2022
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
15/03/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
09/01/2022
MAFR
APPLICATION FILING RECEIPT MAILED
03/12/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
29/11/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
25/11/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ALBAJUNA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.